Heterocycle-containing carboxylic acid derivative and drug containing the same
Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR 6 ═CR 7 — in which R 6 and R 7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.
1. A heterocycle-containing carboxylic acid derivative represented by the following formula (I):
wherein A is a group represented by the following formula (i)
in which (1) E 1 is a nitrogen atom and F 1 , G 1 , H 1 and I 1 , are carbon atoms which may have a substituent; or (2) F 1 is a nitrogen atom and E 1 , G 1 , H 1 and I 1 are carbon atoms which may have a substituent; or (3) H 1 is a nitrogen atom and E 1 , F 1 , G 1 and I 1 are carbon atoms which may have a substituent, R 1 and R 2 are the same or different and each independently represents a hydrogen atom, a halogen atom, a lower alkyl group which may have a substituent, a cycloalkyl group which may have a substituent; a lower alkoxy group which may have a substituent; a cycloalkyloxy group which may have a substituent, an aryl group which may have a substituent, a heteroaryl group which may have a substituent, an aryloxy group which may have a substituent, a heteroaryloxy group which may have a substituent, a cycloalkylalkyl group which may have a substituent, an arylalkyl group which may have a substituent, a heteroarylalkyl group which may have a substituent, a cycloalkylalkyloxy group which may have a substituent, an arylalkyloxy group which may have a substituent, a heteroarylalkyloxy group which may have a substituent, an alkenyl group which may have a substituent or an alkynyl group which may have a substituent, or R 1 and R 2 are coupled together to form a cycloalkylene group which may have a substituent, a carbon group forming said cycloalkylene group may be substituted by a sulfur atom, an oxygen atom, a sulfinyl group, a sulfonyl group or >NR 4 , R 4 representing a hydrogen atom or a lower alkyl group;
B is a heteroarylene group which may have a substituent, an arylene group which may have a substituent, or a group represented by the following formula:
wherein R 5 represents a hydrogen atom or a lower alkyl group; and m 2 stands for 0 to 2; R 8 to R 15 are the same or different and each independently represents a hydrogen atom or a lower alkyl group; X represents an oxygen atom, a sulfur atom or >NR 4 , R 4 having the same meaning as defined above;
D is an arylene group which may have a substituent;
n 1 is one;
M is a hydroxyl group, a lower alkoxy group or a group represented by the following formula: —NR 16 R 17 in which R 16 and R 17 are the same or different and each independently represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a R 17 lower alkoxy group, a hydroxyalkyl group, an aryl group or a heteroaryl group or R 16 and are coupled together with the adjacent nitrogen atom to form an oxygen- or sulfur-containing ring; and
represents a single bond or double bond; or a physiologically acceptable salt thereof.
2. The compound of claim 1 wherein A is
3. The compound of claim 1 wherein B is an arylene group which may have a substituent, a heteroarylene group which may have a substituent or a group represented by the following formula:
wherein R 5 represents a hydrogen atom or a lower alkyl group.
4. The compound of claim 1 wherein B is a heteroarylene group which may have a substituent, a group represented by the formula —CONH—.
5. A pharmaceutical composition comprising a pharmaceutically effective amount of the heterocycle-containing carboxylic acid derivative or physiologically acceptable salts thereof as claimed in claim 1 and a pharmaceutically acceptable carrier.
6. A method for treating acute promyelocytic leukemia by administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or physiologically acceptable salts thereof as claimed in claim 1 to a person suffering from acute promyelocytic leukemia.